0001399529-21-000104.txt : 20210607
0001399529-21-000104.hdr.sgml : 20210607
20210607213258
ACCESSION NUMBER: 0001399529-21-000104
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210603
FILED AS OF DATE: 20210607
DATE AS OF CHANGE: 20210607
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Doberstein Stephen K
CENTRAL INDEX KEY: 0001480111
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36281
FILM NUMBER: 211001086
MAIL ADDRESS:
STREET 1: 129 ELSIE STREET
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94110
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dicerna Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001399529
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205993609
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 75 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617 621 8097
MAIL ADDRESS:
STREET 1: 75 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
wf-form4_162311596214632.xml
FORM 4
X0306
4
2021-06-03
0
0001399529
Dicerna Pharmaceuticals Inc
DRNA
0001480111
Doberstein Stephen K
C/O DICERNA PHARMACEUTICALS, INC.
75 HAYDEN AVENUE
LEXINGTON
MA
02421
1
0
0
0
Common Stock
2021-06-03
4
M
0
3333
A
3333
D
Restricted Stock Units
2021-06-03
4
M
0
3333
0
D
Common Stock
3333.0
0
D
Restricted Stock Units
2021-06-03
4
A
0
3333
0
A
Common Stock
3333.0
3333
D
Director Stock Option (Right to Buy)
30.47
2021-06-03
4
A
0
15000
0
A
2031-06-02
Common Stock
15000.0
15000
D
Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock.
Represents RSUs that vested and became nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on June 3, 2021.
Represents RSUs that shall vest and become nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on the earlier of (i) 12 months from June 3, 2021 ("Grant Date") and (ii) the next regularly scheduled annual meeting of stockholders of the Issuer that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer as a director through such date or, if earlier, such annual meeting.
This option vests monthly over 12 months from the Grant Date in substantially equal monthly installments, provided that the option will vest in full on the next regularly scheduled annual meeting of the stockholders of the Issuer that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting.
/s/ Douglas W. Pagan, attorney-in-fact
2021-06-07